(MRNY) YieldMax MRNA Option Income - Ratings and Ratios
Call Options, MRNA Equity, Put Options, Collateral
Dividends
| Dividend Yield | 13.90% |
| Yield on Cost 5y | 4.13% |
| Yield CAGR 5y | 0.00% |
| Payout Consistency | 100.0% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 53.2% |
| Value at Risk 5%th | 84.6% |
| Relative Tail Risk | -3.35% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.74 |
| Alpha | -56.68 |
| CAGR/Max DD | -0.53 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.463 |
| Beta | 1.056 |
| Beta Downside | 0.894 |
| Drawdowns 3y | |
|---|---|
| Max DD | 82.04% |
| Mean DD | 48.40% |
| Median DD | 65.57% |
Description: MRNY YieldMax MRNA Option Income November 16, 2025
The YieldMax MRNA Option Income Strategy ETF (NYSE ARCA: MRNY) pursues a derivative-based income approach that is tied exclusively to the performance of the mRNA sector, regardless of broader market or economic conditions. When markets turn adverse, the manager may adopt temporary defensive positions, but the fund remains non-diversified, concentrating risk on a single thematic exposure.
Key sector metrics that influence MRNY’s outlook include the global mRNA vaccine market, which is projected to exceed $50 billion by 2028, and the biotech R&D intensity index, currently rising at roughly 7 % YoY, reflecting sustained pipeline activity. Additionally, the implied volatility of mRNA-related equity options-often 30-40 % higher than the broader S&P 500-provides the premium income source that the ETF’s strategy seeks to harvest.
Economic drivers such as FDA regulatory timelines and pandemic-related public-health spending can materially affect the underlying securities, while macro-level factors like interest-rate expectations and inflation pressures influence the cost of carry for option writing strategies.
For a deeper dive into the fund’s risk-adjusted performance metrics, you might explore ValueRay’s analytical toolkit.
What is the price of MRNY shares?
Over the past week, the price has changed by -1.19%, over one month by +6.04%, over three months by +4.86% and over the past year by -38.29%.
Is MRNY a buy, sell or hold?
What are the forecasts/targets for the MRNY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 13.9 | -5.2% |
MRNY Fundamental Data Overview November 26, 2025
Beta = 0.0
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 78.3m USD (78.3m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 78.3m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 78.3m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.91% (E(78.3m)/V(78.3m) * Re(9.91%) + (debt-free company))
Discount Rate = 9.91% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for MRNY ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle